Credit: IMBA/Tibor Kulcsar

UBC scientist discovers trial drug that can significantly block early stages of COVID-19 in engineered human tissues

Posted on

An international team led by UBC researcher Dr. Josef Penninger has found a trial drug that effectively blocks the cellular door SARS-CoV-2 uses to infect its hosts. The findings hold promise as a treatment capable of stopping early infection of the novel coronavirus.

“We are hopeful our results have implications for the development of a novel drug for the treatment of this unprecedented pandemic,” says Penninger, professor in UBC’s faculty of medicine, director of the Life Sciences Institute and the Canada 150 Research Chair in Functional Genetics at UBC….

https://news.ubc.ca/2020/04/02/ubc-led-study-finds-trial-drug-can-significantly-block-early-stages-of-covid-19-in-engineered-human-tissues/

Read More Impact Stories

Posted on
For patients with neuroblastoma, one of the most common solid tumours in children, disease outcomes can vary widely. Some children [...]
Posted on
McMaster researchers have developed the first COVID rapid test for community wastewater, which will make early warning surveillance of infectious [...]
Posted on
Study shows limited impact of pandemic on mental health, underlining strength of human resilience. COVID-19 has taken a relatively limited [...]